MEDIBIOFARMA S L has a total of 16 patent applications. It increased the IP activity by 1300.0%. Its first patent ever was published in 2017. It filed its patents most often in EPO (European Patent Office), Australia and Canada. Its main competitors in its focus markets organic fine chemistry and pharmaceuticals are NANJING FUHAI AOSAI MEDICINE SCIENCE & TECHNOLOGY CO LTD, ANTABIO SAS and PETRUKHIN KONSTANTIN.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 4 | |
#2 | Australia | 2 | |
#3 | Canada | 2 | |
#4 | China | 2 | |
#5 | Republic of Korea | 2 | |
#6 | WIPO (World Intellectual Property Organization) | 2 | |
#7 | Brazil | 1 | |
#8 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Medical preparations | |
#3 | Acyclic or carbocyclic compounds | |
#4 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Castro Palomino Laria Julio | 13 |
#2 | Camacho Gómez Juan | 9 |
#3 | Rodríguez Iglesias Rodolfo | 8 |
#4 | Rodriguez Iglesias Rodolfo | 7 |
#5 | Camacho Gomez Juan | 6 |
#6 | Palomino Laria Julio Castro | 2 |
#7 | Julio Castro Palomino Laria | 1 |
#8 | Velilla Martínez Irene | 1 |
#9 | Juan Camacho Gómez | 1 |
#10 | Rodolfo Rodríguez Iglesias | 1 |
Publication | Filing date | Title |
---|---|---|
EP3693359A1 | New n-benzyl-2-phenoxybenzamide derivatives as prostaglandin e2 (pge2) receptors modulators | |
CA3069273A1 | New heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and/or 2 (hdac1-2) | |
EP3498694A1 | New benzamide derivatives as ppar-gamma modulators |